Segment Information (Details) (USD $)
|
3 Months Ended | 6 Months Ended | |||
---|---|---|---|---|---|
Jun. 30, 2014
|
Jun. 30, 2013
|
Jun. 30, 2014
|
Jun. 30, 2013
|
Dec. 31, 2013
|
|
Segment Information | |||||
Depreciation and amortization | $ 610,515 | $ 7,481 | $ 1,088,619 | $ 16,168 | |
Segment profit | (610,000) | (7,000) | (1,089,000) | (17,000) | |
Operating expenses | 3,897,000 | 8,090,000 | 4,790,000 | 10,139,000 | |
Other (income) expenses | (52,352) | (10,573,737) | (43,697) | (10,316,480) | |
Impact of derivative securities | (9,217,000) | (10,390,000) | |||
Net income (loss) from continuing ops. | (4,455,232) | 2,476,647 | (5,835,407) | 126,778 | |
Loss from discontinued ops. | (129,157) | (256,068) | |||
Preferred dividends | 47,250 | 171,625 | |||
Net loss attributable to common shareholders | (4,455,232) | 2,300,240 | (5,835,407) | (300,915) | |
Assets at end of period | 54,529,269 | 197,000 | 54,529,269 | 197,000 | 18,344,052 |
Liabilities at end of period | 9,232,010 | 8,767,000 | 9,232,010 | 8,767,000 | 11,878,894 |
Bio Pharma
|
|||||
Segment Information | |||||
Depreciation and amortization | 610,000 | 1,089,000 | |||
Segment profit | (610,000) | (1,089,000) | |||
Operating expenses | 3,897,000 | 4,790,000 | |||
Other (income) expenses | (52,000) | (44,000) | |||
Net income (loss) from continuing ops. | (4,455,000) | (5,835,000) | |||
Net loss attributable to common shareholders | (4,455,000) | (5,835,000) | |||
Assets at end of period | 54,529,000 | 54,529,000 | |||
Liabilities at end of period | 9,170,000 | 9,170,000 | |||
ProElite
|
|||||
Segment Information | |||||
Loss from discontinued ops. | (129,000) | (256,000) | |||
Net loss attributable to common shareholders | (129,000) | (256,000) | |||
Assets at end of period | 26,000 | 26,000 | |||
Liabilities at end of period | 62,000 | 1,517,000 | 62,000 | 1,517,000 | |
Other
|
|||||
Segment Information | |||||
Depreciation and amortization | 7,000 | 17,000 | |||
Segment profit | (7,000) | (17,000) | |||
Operating expenses | 8,090,000 | 10,139,000 | |||
Other (income) expenses | (1,356,000) | 107,000 | |||
Impact of derivative securities | (9,217,000) | (10,390,000) | |||
Net income (loss) from continuing ops. | 2,476,000 | (127,000) | |||
Preferred dividends | 47,000 | 172,000 | |||
Net loss attributable to common shareholders | 2,429,000 | (45,000) | |||
Assets at end of period | 172,000 | 172,000 | |||
Liabilities at end of period | $ 7,250,000 | $ 7,250,000 |